CS Paper Radar

Discovery of new antiviral agents through artificial intelligence: in vitro and in vivo results

Roza Izmailyan, Mher Matevosyan, Hamlet Khachatryan, Anastasiya Shavina, Smbat Gevorgyan, Artur Ghazaryan, Irina Tirosyan, Yeva Gabrielyan, Marusya Ayvazyan, Boris Martirosyan, Vardan Harutyunyan, Hovakim Zakaryan

cs.LG q-bio.BM ·submitted 2026-11-17 05:22 UTC · v1
publishedunusual

Abstract

In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60291 compounds were generated, of which 86.5% displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds with non-sialic acid-like structures were selected for in vitro experiments. We identified two compounds, DS-22-inf-009 and DS-22-inf-021 that effectively inhibited the NAs of both influenza A and B viruses (IAV and IBV), including H275Y mutant strains at low micromolar concentrations. Molecular dynamics simulations revealed a similar pattern of interaction with amino acid residues as oseltamivir. In cell-based assays, DS-22-inf-009 and DS-22-inf-021 inhibited IAV and IBV in a dose-dependent manner with EC50 values ranging from 0.29 uM to 2.31 uM. Furthermore, animal experiments showed that both DS-22-inf-009 and DS-22-inf-021 exerted antiviral activity in mice, conferring 65% and 85% protection from IAV (H1N1 pdm09), and 65% and 100% protection from IBV (Yamagata lineage), respectively. Thus, these findings demonstrate the potential of RL to generate compounds with promising antiviral properties.

Comment
Accepted manuscript. 13 pages, 5 figures; supplementary material included (supplementary text, Tables S1-S2, Figures S1-S5). Published in Antiviral Research 222 (2024) 105818
Journal ref
Antiviral Research 222 (2024) 105818
DOI
10.1016/j.antiviral.2024.105818

Closest papers

Nearest neighbours by meaning across the whole index.

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.56
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

MolHop: Scaffold-Hopping Molecular Design with Agentic Reinforcement Learning

cs.LG cs.CL ·2026-10-14 ·Yanyi Su, Chenyan Wang, Yulei Gong, Yeyun Chen, Xiaohui Yang +1 more
similarity 0.52
Abstract · Under review at ICLR 2027

Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represent two fundamentally different search problems. LLM-based molecular design agents typically perform the former, conducting local refinement within the neighborhood of existing structures to improve target properties through structural modifications. In contrast, the latter requires exploration of a broader chemical space to discover molecules with entirely different scaffolds while preserving the functional characteristics of reference molecules. We propose MolHop, an agentic framework for cross-scaffold molecular discovery that enables models to navigate and edit within a pre-organized chemical space. MolHop organizes approximately 1.6 million molecular scaffolds from commercial molecules into a coarse-to-fine hierarchical action space. The agent selects new exploration regions through scaffold navigation actions and adjusts candidate properties through molecular editing. The framework maintains historical trajectory memory to support long-horizon search processes. On drug molecule and commercial compound tasks, connecting Grok-4.6 and DeepSeek-Flash-V4.1 to the MolHop framework substantially improves their cross-scaffold joint success rates. We develop MolHop-9B through agentic reinforcement learning, and MolHop-9B outperforms generative baselines including GPT-5.6-sol, Claude-5-Opus, and Gemini-3.1-Pro, while generating candidate molecules with larger scaffold differences from the reference molecules. These results demonstrate that effective molecular discovery beyond the traditional optimization paradigm requires structured chemical and action spaces, enabling agents to explore new structural regions rather than merely refine existing molecules.

0.19

PGFS++: Molecular Property Improvement under Synthesis and Diversity Constraints

cs.LG cs.AI ·2026-08-19 ·Boqiao Zhang, Godbless James, Sai Krishna Gottipati, Andrew Fitzgibbon
similarity 0.51
Abstract

Improving molecular properties, such as drug-likeness or binding affinity, is a recurring task in early-stage drug discovery. However, molecules optimized in an unconstrained chemical space have limited practical value if they cannot be synthesized. Policy Gradient for Forward Synthesis (PGFS) is a synthesis-aware reinforcement learning method for molecular improvement, but its use of reactant embedding prediction makes reactant selection indirect, which, as we show, limits learning effectiveness. We first develop PGFS+, in which reaction templates and second reactants are represented by trainable embedding lookup tables. Combined with a more effective scoring function and RL algorithm, PGFS+ significantly improves the desired property. However, it exposes a reward-hacking failure mode: a powerful reactant search can map diverse input molecules to the same high-reward magnet molecule, improving the reward while collapsing the output diversity. We therefore introduce PGFS++, a synthesis-aware reinforcement learning framework for input-specific molecular improvement. Given an input molecule, PGFS++ treats it as the start of a forward-synthesis trajectory, applies learned reaction templates with compatible in-stock building blocks, and produces a molecule with improved target properties, an explicit synthesis route, and structural similarity to the input. Experiments on molecular improvement tasks show that PGFS++ improves target properties while preserving high output diversity.

0.21

Vibe synthesis: hierarchical agentic decision-making for intent-driven multistep molecule synthesis

cs.AI physics.chem-ph ·2026-11-12 ·Jie Chen, Guikun Chen, Feng Wan, Ning Xu, Wen Liu +13 more
similarity 0.50
Abstract · 30 pages, 5 figures

The ability to construct complex molecules underpins advances in medicine and the molecular sciences. Yet long-horizon multistep synthesis requires decisions to be revised as evidence accumulates across chemically dependent operations, a capability not readily supported by artificial-intelligence tools and automated platforms organized around predefined tasks and hard-coded workflows. Here we propose and demonstrate a vibe synthesis system (VibeSyn), an intent-driven architecture in which hierarchical agents translate chemist-defined molecular objectives and accumulating evidence into adaptive decisions executed through computational tools and laboratory automation. We evaluate VibeSyn in three demonstrations of increasing scope and autonomy, progressing from evidence-grounded experimental decisions to adaptive execution of a ten-step total synthesis of catharanthine and structure-to-compound synthesis of cyclic peptides containing unnatural amino acids (uAAs). Across the long-horizon campaigns, active human input and simple confirmation account for less than 7.5% and 5.2%, respectively, of recorded workflow actions and outcomes. VibeSyn points towards a future in which chemists define synthetic intent and agent-directed laboratories autonomously navigate the evolving experimental trajectory required to deliver the target compound.

0.24

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

cs.AI ·2026-10-29 ·Yikun Zhang, Xiwei Cheng, Mingze Yuan, Yu Zhang, Brian Shim +13 more
community pick similarity 0.49
Abstract · v2: updated the author list

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here we introduce MoLRSI, an AI agent that combines systematic optimization of workflows and model architectures with persistent cross-task memory to recursively improve its search policy for molecular discovery. Workflow performance, refinement outcomes, and execution feedback guide subsequent searches, allowing the agent to improve both its workflows and its strategy for developing them. We evaluate MoLRSI in two challenging molecular discovery settings that require balancing competing properties. In antibiotic discovery, MoLRSI developed a screening workflow balancing antibacterial activity, cytotoxicity and structural novelty, achieving an experimental hit rate of 15.9%, compared with 8.7% for a previous expert-led workflow using the same training data and screening library. In de novo peptide-MHC binder design, MoLRSI developed workflows that jointly consider target binding and specificity, producing eight experimentally validated hits against MART-1 and SARS-CoV-1 pMHCs with preferential binding over tested off-targets while Claude Science completely failed. These findings demonstrate how experience-guided workflow optimization can address competing discovery objectives while improving the search strategies used in subsequent campaigns.

0.39

MADDIE: Multi-Agent Drug Discovery Engine

cs.AI ·2026-10-12 ·Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao +2 more
code/data similarity 0.49
Abstract

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.

0.49

MFG: Multi-turn Feedback Guided Molecular Optimization

cs.AI cs.LGq-bio.QM ·2026-10-13 ·Trieu Nguyen, Frazier N. Baker, Ruoxi Gao, Daniel Adu-Ampratwum, Xia Ning
similarity 0.49
Abstract

Multi-objective molecular optimization is a critical process in drug discovery that aims to modify a given molecule to simultaneously improve multiple properties while maintaining a similar overall structure. This process often requires iterative modifications guided by computational or experimental feedback. Recent large language model (LLM)-based methods have begun to explore this iterative approach; however, these methods are not explicitly trained to leverage such feedback, while existing approaches primarily focus on single-turn molecular optimization. To address this gap, we introduce Multi-turn Feedback Guided (MFG) molecular optimization, a reinforcement learning framework that trains an LLM to progressively optimize molecules using feedback from previous turns. MFG introduces a feedback vector capturing both property improvements and source molecule similarity, alongside a feedback-aligned reward function that promotes progressive improvement across turns. We apply MFG over $\text{GeLLM}^{3}\text{O}$, a state-of-the-art LLM model for multi-objective molecular optimization, evaluate $\text{GeLLM}^{3}\text{O-MFG}$ on ten multi-objective molecular optimization tasks. The results demonstrate that $\text{GeLLM}^{3}\text{O-MFG}$ achieves the highest average similarity-constrained success rate ($81.50%$), outperforming the base model $\text{GeLLM}^{3}\text{O}$ ($70.81%$).

0.17

Bridging the Evidence-to-Execution Gap:A Reflective Agent for Multi-Objective Peptide Design

cs.AI ·2026-10-05 ·Haosen Zhang, Yang Yang
similarity 0.48
Abstract · 24 pages, 8 figures

Large language models can reason over scientific literature, but textual plans do not reliably produce biological sequences with the intended properties. Sequence generators capture sequence patterns, yet they do not interpret evidence, choose interventions, or reflect on outcomes. This separation creates an evidence-to-execution gap between scientific reasoning and sequence-level control. We introduce EASER, a reflective agent that connects the two through a learned property interface. The interface consists of property-specific low-rank directions trained offline and fixed during search; an LLM controller (the controller) composes them to steer a frozen diffusion generator. From retrieved evidence, sequence context, and prior outcomes, it proposes intervention hypotheses that specify anchors, editable positions, and coefficients. Probe-and-Steer tests these hypotheses and allocates further samples from their joint predicted responses; reflection updates the agent's memory. On computational antimicrobial peptide design, EASER balances activity, non-hemolysis, and non-toxicity. Explicit hypothesis formulation yields larger multi-objective gains than direct action generation, and ablations support evidence retrieval, episodic history, reflection, and Probe-and-Steer. EASER achieves the highest mean hypervolume and lowest mean IGD+ among the evaluated search policies and generators on screened candidates. These results show that a learned property interface can make literature-grounded reasoning executable at the sequence level.

0.28